Executive VP, COO of BioReference Laboratories Inc. (BRLI, Financial) Howard Dubinett sells 85,803 shares of BRLI on 10/19/2009 at an average price of $29.98 a share.
BioReference Laboratories Inc. is the largest independent regional clinical laboratory in the Northeast & has major market positions in physician offices nursing homes & correctional institutions. The Company is a full service clinical laboratory with specialty capability especially in the areas of genomics oncology correctional health & complimentary medicine. PSIMedica a business unit of the Company is a clinical knowledge management organization offering an array of information solutions for reducing healthcare costs & improving quality performance that are based on a flexible scalable software analytical engine that utilizes all available source information including claims data enrollment data prescription data & laboratory data. They provides a comprehensive connectivity solution to physicians as well as other laboratories which includes laboratory reporting & ordering as well as laboratory to physician communications & cumulative reporting through CareEvolve its Bioreference Laboratories Inc. has a market cap of $471.1 million; its shares were traded at around $34.09 with a P/E ratio of 25.1 and P/S ratio of 1.6. Bioreference Laboratories Inc. had an annual average earning growth of 19.8% over the past 5 years.
BioReference Laboratories Inc. is the largest independent regional clinical laboratory in the Northeast & has major market positions in physician offices nursing homes & correctional institutions. The Company is a full service clinical laboratory with specialty capability especially in the areas of genomics oncology correctional health & complimentary medicine. PSIMedica a business unit of the Company is a clinical knowledge management organization offering an array of information solutions for reducing healthcare costs & improving quality performance that are based on a flexible scalable software analytical engine that utilizes all available source information including claims data enrollment data prescription data & laboratory data. They provides a comprehensive connectivity solution to physicians as well as other laboratories which includes laboratory reporting & ordering as well as laboratory to physician communications & cumulative reporting through CareEvolve its Bioreference Laboratories Inc. has a market cap of $471.1 million; its shares were traded at around $34.09 with a P/E ratio of 25.1 and P/S ratio of 1.6. Bioreference Laboratories Inc. had an annual average earning growth of 19.8% over the past 5 years.
Insiders' Positions with BRLI
- Sell:: President, CEO, 10% Owner on 10/07/2009 Marc Grodman sold 29,196 shares of BRLI stock at the average price of 35.19, the price of the stock has decreased by 3.13% since
- Sell:: President, CEO, 10% Owner on 07/09/2009 Marc Grodman sold 35,000 shares of BRLI stock at the average price of 30.37, the price of the stock has increased by 12.25% since
Insiders' Positions with BRLI
- Sell:: Sr. VP, Sec'y, Treasurer, CFO on 09/04/2009 Sam Singer sold 4,300 shares of BRLI stock at the average price of 34.76, the price of the stock has decreased by 1.93% since
- Sell:: Sr. VP, Sec'y, Treasurer, CFO on 07/14/2009 Sam Singer sold 16,500 shares of BRLI stock at the average price of 30, the price of the stock has increased by 13.63% since
- Sell:: Sr. VP, Sec'y, Treasurer, CFO on 06/08/2009 Sam Singer sold 16,000 shares of BRLI stock at the average price of 30.47, the price of the stock has increased by 11.88% since
Insiders' Positions with BRLI
- Sell:: Director on 10/05/2009 Gary Lederman sold 12,000 shares of BRLI stock at the average price of 35.24, the price of the stock has decreased by 3.26% since
